JP2021502816A - δ3γδT細胞集団の選択的増殖方法及びその組成物 - Google Patents
δ3γδT細胞集団の選択的増殖方法及びその組成物 Download PDFInfo
- Publication number
- JP2021502816A JP2021502816A JP2020526478A JP2020526478A JP2021502816A JP 2021502816 A JP2021502816 A JP 2021502816A JP 2020526478 A JP2020526478 A JP 2020526478A JP 2020526478 A JP2020526478 A JP 2020526478A JP 2021502816 A JP2021502816 A JP 2021502816A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell population
- cell
- antibody
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 160
- 239000000203 mixture Substances 0.000 title description 86
- 230000035755 proliferation Effects 0.000 title description 67
- 239000012634 fragment Substances 0.000 claims abstract description 95
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 210000004027 cell Anatomy 0.000 claims description 1257
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 467
- 206010028980 Neoplasm Diseases 0.000 claims description 148
- 239000012190 activator Substances 0.000 claims description 99
- 230000027455 binding Effects 0.000 claims description 98
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 75
- 230000012010 growth Effects 0.000 claims description 58
- 230000000694 effects Effects 0.000 claims description 36
- 201000011510 cancer Diseases 0.000 claims description 35
- 230000006052 T cell proliferation Effects 0.000 claims description 34
- 150000007523 nucleic acids Chemical class 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 32
- 230000003013 cytotoxicity Effects 0.000 claims description 31
- 231100000135 cytotoxicity Toxicity 0.000 claims description 31
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 28
- 230000000259 anti-tumor effect Effects 0.000 claims description 27
- 102100027207 CD27 antigen Human genes 0.000 claims description 26
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 26
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 18
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 18
- 230000001419 dependent effect Effects 0.000 claims description 16
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 14
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 14
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 14
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 14
- 210000000265 leukocyte Anatomy 0.000 claims description 14
- 108010087819 Fc receptors Proteins 0.000 claims description 13
- 102000009109 Fc receptors Human genes 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 210000005259 peripheral blood Anatomy 0.000 claims description 11
- 239000011886 peripheral blood Substances 0.000 claims description 11
- 210000004700 fetal blood Anatomy 0.000 claims description 10
- 208000027866 inflammatory disease Diseases 0.000 claims description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 7
- 238000002617 apheresis Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 82
- 238000010586 diagram Methods 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 133
- 108091007433 antigens Proteins 0.000 description 133
- 102000036639 antigens Human genes 0.000 description 133
- 235000001014 amino acid Nutrition 0.000 description 105
- 150000001413 amino acids Chemical class 0.000 description 101
- 108091008874 T cell receptors Proteins 0.000 description 84
- 108090000623 proteins and genes Proteins 0.000 description 80
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 79
- 230000035772 mutation Effects 0.000 description 61
- 241000282414 Homo sapiens Species 0.000 description 56
- -1 CD137 Proteins 0.000 description 46
- 230000004913 activation Effects 0.000 description 46
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 39
- 230000014509 gene expression Effects 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 37
- 108090000765 processed proteins & peptides Proteins 0.000 description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 33
- 230000032823 cell division Effects 0.000 description 30
- 102000004196 processed proteins & peptides Human genes 0.000 description 30
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 28
- 239000003446 ligand Substances 0.000 description 27
- 102000005962 receptors Human genes 0.000 description 27
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 27
- 102000040430 polynucleotide Human genes 0.000 description 26
- 108091033319 polynucleotide Proteins 0.000 description 26
- 239000002157 polynucleotide Substances 0.000 description 26
- 201000010099 disease Diseases 0.000 description 25
- 238000000338 in vitro Methods 0.000 description 25
- 108020003175 receptors Proteins 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 20
- 230000003213 activating effect Effects 0.000 description 19
- 230000006870 function Effects 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 16
- 108010002350 Interleukin-2 Proteins 0.000 description 16
- 102000000588 Interleukin-2 Human genes 0.000 description 16
- 241000700605 Viruses Species 0.000 description 16
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 15
- 241000282412 Homo Species 0.000 description 15
- 230000004663 cell proliferation Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 108700028369 Alleles Proteins 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 14
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 13
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 13
- 102000018358 immunoglobulin Human genes 0.000 description 13
- 238000002955 isolation Methods 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 12
- 238000013507 mapping Methods 0.000 description 12
- 102100025221 CD70 antigen Human genes 0.000 description 11
- 239000012636 effector Substances 0.000 description 11
- 210000004408 hybridoma Anatomy 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 210000000822 natural killer cell Anatomy 0.000 description 11
- 230000002062 proliferating effect Effects 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 10
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 10
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 10
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 10
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 10
- 102000004856 Lectins Human genes 0.000 description 10
- 108090001090 Lectins Proteins 0.000 description 10
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 239000002523 lectin Substances 0.000 description 10
- 230000007170 pathology Effects 0.000 description 10
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 9
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 9
- 102000054766 genetic haplotypes Human genes 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 8
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 8
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 8
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 8
- 102000043129 MHC class I family Human genes 0.000 description 8
- 108091054437 MHC class I family Proteins 0.000 description 8
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 8
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 8
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 8
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 201000001981 dermatomyositis Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 101710186708 Agglutinin Proteins 0.000 description 7
- 241000589562 Brucella Species 0.000 description 7
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 7
- 101710146024 Horcolin Proteins 0.000 description 7
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 7
- 101710189395 Lectin Proteins 0.000 description 7
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 7
- 101710179758 Mannose-specific lectin Proteins 0.000 description 7
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 7
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 7
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 7
- 230000006044 T cell activation Effects 0.000 description 7
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 7
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 7
- 239000000910 agglutinin Substances 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 108020005243 folate receptor Proteins 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 6
- 241000193403 Clostridium Species 0.000 description 6
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 6
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 6
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000010362 genome editing Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 239000010445 mica Substances 0.000 description 6
- 229910052618 mica group Inorganic materials 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000003289 regulatory T cell Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 5
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 5
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 5
- 101001050318 Homo sapiens Junctional adhesion molecule-like Proteins 0.000 description 5
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 5
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 5
- 108090000172 Interleukin-15 Proteins 0.000 description 5
- 102100027670 Islet amyloid polypeptide Human genes 0.000 description 5
- 102100023437 Junctional adhesion molecule-like Human genes 0.000 description 5
- 101150071882 US17 gene Proteins 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- 102000006815 folate receptor Human genes 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 4
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
- 102100025278 Coxsackievirus and adenovirus receptor Human genes 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108010058611 Helix lectin Proteins 0.000 description 4
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 4
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 4
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 description 4
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 4
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 description 4
- 102100033467 L-selectin Human genes 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- 102100039373 Membrane cofactor protein Human genes 0.000 description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 description 4
- 102100023123 Mucin-16 Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 229940126530 T cell activator Drugs 0.000 description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000833 heterodimer Substances 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- CBIDRCWHNCKSTO-UHFFFAOYSA-N prenyl diphosphate Chemical compound CC(C)=CCO[P@](O)(=O)OP(O)(O)=O CBIDRCWHNCKSTO-UHFFFAOYSA-N 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 108010048090 soybean lectin Proteins 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 229950010342 uridine triphosphate Drugs 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 3
- 101001089022 Axinella polypoides Lectin-2 Proteins 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 3
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 3
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 3
- 108010075704 HLA-A Antigens Proteins 0.000 description 3
- 108010058607 HLA-B Antigens Proteins 0.000 description 3
- 108010052199 HLA-C Antigens Proteins 0.000 description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 102100025390 Integrin beta-2 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 3
- 101150069255 KLRC1 gene Proteins 0.000 description 3
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 3
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 3
- 108091092878 Microsatellite Proteins 0.000 description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 3
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 240000007019 Oxalis corniculata Species 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 3
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 3
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 3
- 102100022748 Wilms tumor protein Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 108010074108 interleukin-21 Proteins 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 208000005987 polymyositis Diseases 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000009258 tissue cross reactivity Effects 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 description 2
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 101150051188 Adora2a gene Proteins 0.000 description 2
- 244000099147 Ananas comosus Species 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102100036302 C-C chemokine receptor type 6 Human genes 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 102100026194 C-type lectin domain family 2 member B Human genes 0.000 description 2
- 102100026197 C-type lectin domain family 2 member D Human genes 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 101710185679 CD276 antigen Proteins 0.000 description 2
- 102100027221 CD81 antigen Human genes 0.000 description 2
- 101150034344 CT83 gene Proteins 0.000 description 2
- 108091058556 CTAG1B Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 description 2
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 101150091887 Ctla4 gene Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100020760 Ferritin heavy chain Human genes 0.000 description 2
- GVVPGTZRZFNKDS-YFHOEESVSA-N Geranyl diphosphate Natural products CC(C)=CCC\C(C)=C/COP(O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-YFHOEESVSA-N 0.000 description 2
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 2
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 2
- 108010010378 HLA-DP Antigens Proteins 0.000 description 2
- 102000015789 HLA-DP Antigens Human genes 0.000 description 2
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 208000001204 Hashimoto Disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 2
- 101000912618 Homo sapiens C-type lectin domain family 2 member B Proteins 0.000 description 2
- 101000912615 Homo sapiens C-type lectin domain family 2 member D Proteins 0.000 description 2
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 2
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 2
- 101001002987 Homo sapiens Ferritin heavy chain Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 2
- 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 2
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 2
- 101001005720 Homo sapiens Melanoma-associated antigen 4 Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 2
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 2
- 101000880774 Homo sapiens Protein SSX4 Proteins 0.000 description 2
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 2
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 2
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 101000685848 Homo sapiens Zinc transporter ZIP6 Proteins 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000037977 Immune checkpoint ligands Human genes 0.000 description 2
- 108091008029 Immune checkpoint ligands Proteins 0.000 description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 108050009288 Interleukin-19 Proteins 0.000 description 2
- 101710154942 Interleukin-2 receptor subunit beta Proteins 0.000 description 2
- 108010065637 Interleukin-23 Proteins 0.000 description 2
- 102000013264 Interleukin-23 Human genes 0.000 description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 2
- 108010067003 Interleukin-33 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 101150018199 KLRC4 gene Proteins 0.000 description 2
- 102100021533 Kita-kyushu lung cancer antigen 1 Human genes 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 2
- 102100025077 Melanoma-associated antigen 4 Human genes 0.000 description 2
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 2
- 102100022700 NKG2-F type II integral membrane protein Human genes 0.000 description 2
- 102000002356 Nectin Human genes 0.000 description 2
- 108060005251 Nectin Proteins 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 108091081548 Palindromic sequence Proteins 0.000 description 2
- 108010046016 Peanut Agglutinin Proteins 0.000 description 2
- 241000219833 Phaseolus Species 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 108010089814 Plant Lectins Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 2
- 102100037686 Protein SSX2 Human genes 0.000 description 2
- 102100037727 Protein SSX4 Human genes 0.000 description 2
- 101710161300 Protein peanut Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108091007561 SLC44A4 Proteins 0.000 description 2
- 240000006028 Sambucus nigra Species 0.000 description 2
- 235000003142 Sambucus nigra Nutrition 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 101800001271 Surface protein Proteins 0.000 description 2
- 102100035721 Syndecan-1 Human genes 0.000 description 2
- IDCBOTIENDVCBQ-UHFFFAOYSA-N TEPP Chemical compound CCOP(=O)(OCC)OP(=O)(OCC)OCC IDCBOTIENDVCBQ-UHFFFAOYSA-N 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 102000008579 Transposases Human genes 0.000 description 2
- 108010020764 Transposases Proteins 0.000 description 2
- 102100033579 Trophoblast glycoprotein Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100039094 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 2
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000219873 Vicia Species 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 102100023144 Zinc transporter ZIP6 Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- ZJXZSIYSNXKHEA-UHFFFAOYSA-L ethyl phosphate(2-) Chemical compound CCOP([O-])([O-])=O ZJXZSIYSNXKHEA-UHFFFAOYSA-L 0.000 description 2
- 235000008995 european elder Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 102000036215 folic acid binding proteins Human genes 0.000 description 2
- 108091011001 folic acid binding proteins Proteins 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 2
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000000564 macroglobulinemia Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000003726 plant lectin Substances 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000037968 sinus cancer Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000004500 stellate cell Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- MDSIZRKJVDMQOQ-GORDUTHDSA-N (2E)-4-hydroxy-3-methylbut-2-en-1-yl diphosphate Chemical compound OCC(/C)=C/COP(O)(=O)OP(O)(O)=O MDSIZRKJVDMQOQ-GORDUTHDSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- KIJIIIDYDGXWFJ-UHFFFAOYSA-N 3-formylbutyl diphosphate Chemical compound O=CC(C)CCOP(O)(=O)OP(O)(O)=O KIJIIIDYDGXWFJ-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 241001533362 Astroviridae Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000037914 B-cell disorder Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 241001302512 Banna virus Species 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241001148111 Brucella suis Species 0.000 description 1
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 1
- 102100027138 Butyrophilin subfamily 3 member A1 Human genes 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
- 102100031102 C-C motif chemokine 4 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 108010046080 CD27 Ligand Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108010058905 CD44v6 antigen Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 102100024154 Cadherin-13 Human genes 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010083702 Chemokine CCL21 Proteins 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 201000005019 Chlamydia pneumonia Diseases 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 206010008685 Chondritis Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 101710176411 Coxsackievirus and adenovirus receptor Proteins 0.000 description 1
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000010772 Dog disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 102100023431 E3 ubiquitin-protein ligase TRIM21 Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101150016325 EPHA3 gene Proteins 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100032558 Glypican-2 Human genes 0.000 description 1
- 102100032530 Glypican-3 Human genes 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 241000190708 Guanarito mammarenavirus Species 0.000 description 1
- 108010066705 H-cadherin Proteins 0.000 description 1
- 101150090209 HCST gene Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 description 1
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
- 108010051539 HLA-DR2 Antigen Proteins 0.000 description 1
- 108010064885 HLA-DR3 Antigen Proteins 0.000 description 1
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
- 241000893570 Hendra henipavirus Species 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 241001122120 Hepeviridae Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000984934 Homo sapiens Butyrophilin subfamily 3 member A1 Proteins 0.000 description 1
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 description 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000685877 Homo sapiens E3 ubiquitin-protein ligase TRIM21 Proteins 0.000 description 1
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 description 1
- 101100334524 Homo sapiens FCGR3B gene Proteins 0.000 description 1
- 101001014664 Homo sapiens Glypican-2 Proteins 0.000 description 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 description 1
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 101100232357 Homo sapiens IL13RA1 gene Proteins 0.000 description 1
- 101100232360 Homo sapiens IL13RA2 gene Proteins 0.000 description 1
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917821 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-c Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 description 1
- 101100101727 Homo sapiens RAET1L gene Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 1
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
- 101000607306 Homo sapiens UL16-binding protein 1 Proteins 0.000 description 1
- 101000607320 Homo sapiens UL16-binding protein 2 Proteins 0.000 description 1
- 101000607318 Homo sapiens UL16-binding protein 3 Proteins 0.000 description 1
- 241001479210 Human astrovirus Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000046923 Human bocavirus Species 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100022341 Integrin alpha-E Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 101710123028 Integrin alpha-X Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000219739 Lens Species 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 1
- 102100029206 Low affinity immunoglobulin gamma Fc region receptor II-c Human genes 0.000 description 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 102000010836 Lymphocyte Homing Receptors Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 241000712898 Machupo mammarenavirus Species 0.000 description 1
- 108010030317 Macrophage-1 Antigen Proteins 0.000 description 1
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 1
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 108091092919 Minisatellite Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 101000777470 Mus musculus C-C motif chemokine 4 Proteins 0.000 description 1
- 101001092200 Mus musculus RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- 101150065403 NECTIN2 gene Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 108010077854 Natural Killer Cell Receptors Proteins 0.000 description 1
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 1
- 102100035488 Nectin-2 Human genes 0.000 description 1
- 102100035487 Nectin-3 Human genes 0.000 description 1
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 206010069493 Perennial allergy Diseases 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241001631648 Polyomaviridae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 201000008183 Pulmonary blastoma Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 241000607758 Shigella sp. Species 0.000 description 1
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 description 1
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010083312 T-Cell Antigen Receptor-CD3 Complex Proteins 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 101150069237 TYROBP gene Proteins 0.000 description 1
- 101001051488 Takifugu rubripes Neural cell adhesion molecule L1 Proteins 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241001467018 Typhis Species 0.000 description 1
- 102100040012 UL16-binding protein 1 Human genes 0.000 description 1
- 102100039989 UL16-binding protein 2 Human genes 0.000 description 1
- 102100040011 UL16-binding protein 3 Human genes 0.000 description 1
- 102100040013 UL16-binding protein 6 Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 101710127857 Wilms tumor protein Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- MYSMBSLUBMFKKQ-SDBHATRESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-5-(3-methylbut-3-enyl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=NC2=C(N)N=CN=C2N1[C@]1(CCC(=C)C)O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O MYSMBSLUBMFKKQ-SDBHATRESA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006786 activation induced cell death Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 201000002454 adrenal cortex cancer Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HGLAYHSJJRYIBI-UHFFFAOYSA-N allyl diphosphate Chemical compound OP(O)(=O)OP(O)(=O)OCC=C HGLAYHSJJRYIBI-UHFFFAOYSA-N 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000008873 bone osteosarcoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000009960 carding Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 108700041286 delta Proteins 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 108010039433 dolichos biflorus agglutinin Proteins 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- OJDJHGIXNZPZFD-UHFFFAOYSA-N ethyl dihydrogen diphosphate Chemical compound CCO[P@](O)(=O)OP(O)(O)=O OJDJHGIXNZPZFD-UHFFFAOYSA-N 0.000 description 1
- ISCLZDJGLPCZAS-WOUKDFQISA-N ethyl-ATP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ISCLZDJGLPCZAS-WOUKDFQISA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 description 1
- 229950010333 exalamide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 208000014796 hyper-IgE recurrent infection syndrome 1 Diseases 0.000 description 1
- 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
- 201000004108 hypersplenism Diseases 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 description 1
- 108040006856 interleukin-3 receptor activity proteins Proteins 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 108010034897 lentil lectin Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- DLEDLHFNQDHEOJ-UDTOXTEMSA-N mezerein Chemical compound O([C@@H]1[C@H]([C@@]23[C@H]4[C@](C(C(C)=C4)=O)(O)[C@H](O)[C@@]4(CO)O[C@H]4[C@H]3[C@H]3O[C@@](O2)(O[C@]31C(C)=C)C=1C=CC=CC=1)C)C(=O)\C=C\C=C\C1=CC=CC=C1 DLEDLHFNQDHEOJ-UDTOXTEMSA-N 0.000 description 1
- DLEDLHFNQDHEOJ-KVZAMRGJSA-N mezerein Natural products CC1C(OC(=O)C=C/C=C/c2ccccc2)C3(OC4(OC3C5C6OC6(CO)C(O)C7(O)C(C=C(C)C7=O)C15O4)c8ccccc8)C(=C)C DLEDLHFNQDHEOJ-KVZAMRGJSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000017708 myomatous neoplasm Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000001254 nonsecretory effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical class NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 208000030773 pneumonia caused by chlamydia Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 102200041252 rs118203942 Human genes 0.000 description 1
- 102200024820 rs121908819 Human genes 0.000 description 1
- 102200064131 rs137852228 Human genes 0.000 description 1
- 102220011021 rs397507516 Human genes 0.000 description 1
- 102220295004 rs781303622 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000029138 selective IgA deficiency disease Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 108010043166 wisteria lectin Proteins 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本願は、2017年11月15日に出願された米国仮出願第62/586,782号の優先権の利益を主張するものであり、この出願の内容はその全体が全目的でこれをもって援用される。
本明細書で言及される全ての刊行物、特許、及び特許出願は、あたかも各個別の刊行物、特許、または特許出願が、明確かつ個別に参照により援用されることが示されているかのように同程度に、参照により本明細書に援用される。
別途規定されない限り、本明細書で使用される全ての技術用語及び科学用語は、本明細書に記載される本発明の属する技術分野における通常の知識を有する者に一般的に理解される意味と同じ意味を有する。本明細書を解釈する目的において、以下の定義が適用され、適切な場合はいつでも、単数形で使用される用語は複数形もまた含み、その逆も同様である。記載されるいずれかの定義が、参照により本明細書に援用されるいずれかの文献と矛盾する場合には、以下に記載される定義が優先する。
ヒトにおいて、γδT細胞(複数可)は、自然免疫応答と適応免疫応答との間の連係を提供するT細胞のサブセットである。これらの細胞は、V−(D)−Jセグメント再構成を経て、抗原特異的なγδT細胞受容体(γδTCR)、及びγδT細胞(複数可)を生成し、γδTCR、またはγδT細胞エフェクター機能を活性化させるように独立してもしくは一緒に作用する他の非TCRタンパク質のいずれかによる抗原の認識を介して、直接活性化され得る。γδT細胞は、哺乳動物において、末梢血及びリンパ器官中のT細胞のおよそ1〜5%と、全体的なT細胞集団のごく一部に相当し、それらは、皮膚、肝臓、消化管、気道、及び生殖管のような上皮細胞に富む区画に主として常在するようである。主要組織適合複合体分子(MHC)に結合した抗原を認識する、αβTCRとは異なり、γδTCRは、細菌抗原、ウイルス抗原、病的細胞により発現されるストレス抗原、及び無傷のタンパク質または非ペプチド化合物の形態の腫瘍抗原を直接認識することができる。
一部の態様では、本発明は、操作型または非操作型γδT細胞の増殖のためのエクスビボ方法を提供する。一部の実例では、該方法は、IL−4、IL−2、もしくはIL−15、またはそれらの組み合わせ等の、特定のγδT細胞集団の増殖に有利なサイトカインを含まない、1つまたは複数の(例えば、第1及び/または第2の)増殖ステップを採用する。一部の実施形態では、本発明は、混合細胞集団を、δ3TCR(例えば、δ3γδTCR)に特有のエピトープに結合することによってδ3T細胞を選択的に増殖させる1つまたは複数の薬剤と接触させて、濃縮γδT細胞集団をもたらすことを含む、単離された混合細胞集団から濃縮γδT細胞集団を生産するためのエクスビボ方法を提供する。
他の態様では、本開示は、養子移入療法に向けた非操作型及び操作型γδT細胞の集団のエクスビボ増殖のための方法を提供する。本開示の非操作型または操作型γδT細胞は、エクスビボで増殖させてもよい。本開示の非操作型または操作型γδT細胞は、APCによる活性化を伴わずに、あるいはAPC及び/またはアミノホスホネートとの共培養を伴わずに、インビトロで増殖させることができる。追加として、または代替として、本開示の非操作型または操作型γδT細胞は、APCによる活性化、あるいはAPC及び/または1つもしくは複数のアミノホスホネートとの共培養を含む、少なくとも1つの増殖ステップを用いて、インビトロで増殖させることができる。
操作型γδT細胞(例えば、δ3γδT細胞)は、当該技術分野で既知の種々の方法により生成されてもよい。操作型γδT細胞は、特定の腫瘍認識部分を安定に発現するように設計されてもよい。腫瘍認識部分または別の種類の認識部分を含む発現カセットをコードするポリヌクレオチドは、トランスポゾン/トランスポサーゼ系またはレンチウイルスもしくはレトロウイルス系等のウイルスに基づく遺伝子移入系、または別の好適な方法、例えば、トランスフェクション、電気穿孔、形質導入、リポフェクション、リン酸カルシウム(CaPO4)、Ormosil等のナノ操作型物質、アデノウイルス、レトロウイルス、レンチウイルス、アデノ随伴ウイルスを含めたウイルス送達法、または別の好適な方法によって、γδT細胞に安定に導入することができる。αβまたはγδのいずれかである抗原特異的TCRは、抗原特異的TCRの遺伝コードを含むポリヌクレオチドをγδT細胞のゲノムに安定に挿入することによって、操作型γδT細胞に導入することができる。腫瘍認識部分を有するCARをコードするポリヌクレオチドは、当該ポリヌクレオチドをγδT細胞のゲノムに安定に挿入することによって、操作型γδT細胞に導入されてもよい。一部の実例では、操作された腫瘍認識部分は、操作されたT細胞受容体であり、操作型γδT細胞のゲノムに組み込まれた発現カセットは、操作されたTCRα(TCRアルファ)遺伝子、操作されたTCRβ(TCRベータ)遺伝子、TCRδ(TCRデルタ)遺伝子、または操作されたTCRγ(TCRガンマ)遺伝子をコードするポリヌクレオチドを含む。一部の実例では、操作型γδT細胞のゲノムに組み込まれた発現カセットは、抗体断片またはその抗原結合部分をコードするポリヌクレオチドを含む。一部の実例では、抗体断片またはその抗原結合断片は、キメラ抗原受容体(CAR)構築物、またはCARとT細胞受容体(TCR)とを含む、もしくはCARと異なる抗原に向けられた抗体とを含む二重特異性構築物の一部として細胞表面腫瘍抗原に結合する、全抗体、抗体断片、1本鎖可変断片(scFv)、単一ドメイン抗体(sdAb)、Fab、F(ab)2、Fc、抗体上の軽鎖もしくは重鎖、抗体の可変もしくは定常領域、またはそれらの任意の組み合わせをコードするポリヌクレオチドである。一部の実例では、ポリヌクレオチドは、ヒトに由来するか、または別の種に由来する。非ヒト種に由来する抗体断片または抗原結合断片ポリヌクレオチドは、ヒトにおいて天然に産生される抗体バリアントへのそれらの類似性を増加させるように改変することができ、抗体断片または抗原結合断片は、部分的または完全にヒト化され得る。抗体断片または抗原結合断片ポリヌクレオチドはまた、キメラ、例えばマウス−ヒト抗体キメラであることもできる。CARを発現する操作型γδT細胞はまた、腫瘍認識部分によって認識される抗原に対するリガンドを発現するように操作することもできる。
操作型γδT細胞は、対象の身体内の特定の物理的位置に帰巣し得る。操作型γδT細胞の遊走及び帰巣は、特定のケモカイン及び/または接着分子の発現及び作用の組み合わせに依存し得る。操作型γδT細胞の帰巣は、ケモカインとそれらの受容体との間の相互作用によって制御され得る。例えば、CXCR3(そのリガンドは、IP−10/CXCL10及び6Ckine/SLC/CCL21により表される)、CCR4+ CXCR5+(RANTES、MIP−1α、MIP−1βに対する受容体)、CCR6+、及びCCR7を含むが、これらに限定されないサイトカインが、操作型γδT細胞の帰巣に影響を及ぼし得る。一部の実例では、操作型γδT細胞は、炎症及び損傷の部位、ならびに病的細胞に帰巣して、修復機能を果たし得る。一部の実例では、操作型γδT細胞は、がんに帰巣することができる。一部の実例では、操作型γδT細胞は、胸腺、骨髄、皮膚、喉頭、気管、胸膜、肺、食道、腹部、胃、小腸、大腸、肝臓、膵臓、腎臓、尿道、膀胱、精巣、前立腺、精管、卵巣、尿管(uretus)、乳腺、副甲状腺、脾臓、または対象の身体内の別の部位に帰巣し得る。操作型γδT細胞は、特定のTCR対立遺伝子及び/またはリンパ球帰巣分子等の、1つまたは複数の帰巣部分を発現することができる。
本明細書に開示される本発明は、抗原認識部分を発現する操作型γδT細胞を提供し、ここで、抗原認識部分は、疾患特有のエピトープを認識する。抗原は、免疫応答を惹起する分子であり得る。この免疫応答は、抗体産生、特定の免疫担当細胞の活性化のいずれか、または両方を伴い得る。抗原は、例えば、ペプチド、タンパク質、ハプテン、脂質、炭水化物、細菌、病原体、またはウイルスであり得る。抗原は、腫瘍抗原であり得る。腫瘍エピトープは、MHC IまたはMHC II複合体によって腫瘍細胞の表面上で提示され得る。エピトープは、細胞表面上で発現され、腫瘍認識部分によって認識される、抗原の部分であり得る。
本発明の発明者らは、γδTCRの特定のサブタイプに結合し、それによってγδT細胞の特定の集団を活性化させ、増殖させる活性化剤を同定した。一態様では、本発明は、本明細書の実施例1及び2、ならびに図1で同定され、記載される、新規の活性化エピトープに結合する新規の活性化剤を提供する。活性化剤には、MAbであるδ3−08、δ3−20、δ3−23、δ3−31、δ3−42、δ3−47、及びδ3−58が含まれるが、これらに限定されない。ある特定の実施形態では、活性化剤(例えば、抗体)は、1つまたは複数のγδT細胞集団(例えば、δ3T細胞)を増殖させ、及び/または活性化させる。
本明細書ではまた、γδT細胞の1つまたは複数の亜集団等の操作型または非操作型γδT細胞の増殖のためのAPCも記載される。一部の実施形態では、上述の活性化剤のうちの1つまたは複数をコードする異種核酸を含有するAPCが本明細書に記載される。一部の実施形態では、上述の活性化剤のうちの1つまたは複数を細胞表面上に発現するAPCが本明細書に記載される。一部の実施形態では、1つまたは複数のFc受容体をその細胞表面上に発現するAPCが本明細書に記載され、ここで、Fc受容体(複数可)は、上述の活性化剤のうちの1つもしくは複数と接触する、及び/またはそれに結合するものである。
本発明の発明者らは、γδTCR活性化MAbであるδ3−08、δ3−20、δ3−23、δ3−31、δ3−42、δ3−47、及びδ3−58のエピトープ内の結合領域を同定した。例となるエピトープには、γδTCR活性化MAbであるδ3−08、δ3−20、δ3−23、δ3−31、δ3−42、δ3−47、及びδ3−58のエピトープが含まれるが、これらに限定されない。一部の実施形態では、エピトープは、γδTCR活性化MAbであるδ3−08、δ3−20、δ3−23、δ3−31、δ3−42、δ3−47、及びδ3−58のうちの1つまたは複数が特異的に結合するエピトープである。
一部の実施形態では、目的とする活性化剤は、1つまたは複数のビン1A抗体であるδ3−23、δ3−42、及び/またはδ3−58のγ2δ3TCRへの結合と競合する。一部の実施形態では、目的とする活性化剤は、ビン1B抗体であるδ3−08のγ2δ3TCRへの結合と競合する。一部の実施形態では、目的とする活性化剤は、1つまたは複数のビン1(ビン1A及びビン1B)抗体であるδ3−23、δ3−42、δ3−58、及び/またはδ3−08のγ2δ3TCRへの結合と競合する。一部の実施形態では、目的とする活性化剤は、ビン2抗体であるδ3−31のγ2δ3TCRへの結合と競合する。
本明細書に記載されるような、非操作型の濃縮γδT細胞集団、操作型の濃縮γδT細胞集団、及び/またはそれらの混和物を含有する薬学的組成物は、予防的及び/または治療的処置のために投与されてもよい。治療用途において、本組成物は、疾患または病態を既に患っている対象に、疾患または病態の症状を治癒させるか、または少なくとも部分的に停止させるのに十分な量で投与され得る。非操作型の濃縮γδT細胞集団、操作型の濃縮γδT細胞集団、及び/またはそれらの混和物はまた、病態の発症、罹患、または悪化の可能性を減らすために投与することもできる。治療的使用のための非操作型の濃縮γδT細胞集団、操作型の濃縮γδT細胞集団、及び/またはそれらの混和物の集団の有効量は、疾患または病態の重症度及び経過、以前の療法、対象の健康状態、体重、及び/または薬物への応答、及び/または処置する医師の判断に基づいて様々であり得る。
本発明の1つまたは複数の非操作型の濃縮γδT細胞集団、操作型の濃縮γδT細胞集団、及び/またはそれらの混和物は、任意の順序でまたは同時に対象に投与され得る。同時の場合、本発明の複数の非操作型の濃縮γδT細胞集団、操作型の濃縮γδT細胞集団、及び/またはそれらの混和物は、静脈内注射等の単一化された単回形態で、または複数回形態で、例えば、複数回の静脈内注入、皮下注射、もしくは丸剤として、提供され得る。本発明の非操作型の濃縮γδT細胞集団、操作型の濃縮γδT細胞集団、及び/またはそれらの混和物は、単一のパッケージ中または複数のパッケージ中で、一緒にまたは別々に包装することができる。本発明の非操作型の濃縮γδT細胞集団、操作型の濃縮γδT細胞集団、及び/またはそれらの混和物のうちの1つまたは全てを複数回用量で与えることができる。同時でない場合、複数回用量の間のタイミングは、約1週間、1ヶ月間、2ヶ月間、3ヶ月間、4ヶ月間、5ヶ月間、6ヶ月間、または約1年間もの長さまで様々であり得る。一部の実例では、本発明の非操作型の濃縮γδT細胞集団、操作型の濃縮γδT細胞集団、及び/またはそれらの混和物は、対象への投与後に、対象の身体内においてインビボで増殖することができる。非操作型の濃縮γδT細胞集団、操作型の濃縮γδT細胞集団、及び/またはそれらの混和物は凍結させて、同じ細胞調製物による複数回処置のための細胞をもたらすことができる。本開示の非操作型の濃縮γδT細胞集団、操作型の濃縮γδT細胞集団、及び/またはそれらの混和物、ならびにそれらを含む薬学的組成物は、キットとして包装することができる。キットは、非操作型の濃縮γδT細胞集団、操作型の濃縮γδT細胞集団、及び/またはそれらの混和物、ならびにそれらを含む薬学的組成物の使用に関する説明書(例えば、文書による説明書)を含んでもよい。
本明細書に開示されるような非操作型の濃縮γδT細胞集団、操作型の濃縮γδT細胞集団、及び/またはそれらの混和物は、正確な投薬量の単回投与に好適な単位剤形で製剤化されてもよい。一部の実例では、単位剤形は、追加のリンパ球を含む。単位剤形において、製剤は、1つまたは複数の化合物の適切な分量を含有する単位用量に分割される。単位投薬量は、製剤の個別的な分量を含有するパッケージの形態であり得る。非限定的な例は、包装された錠剤またはカプセル剤、及びバイアルまたはアンプル中の粉末である。水性懸濁液組成物は、単回用量の再封不可能容器中に包装することができる。複数回用量の再封可能容器は、例えば、防腐剤と組み合わせてまたは防腐剤なしで、使用することができる。一部の例では、薬学的組成物は、防腐剤を含まない。非経口投与用の製剤は、単位剤形で、例えばアンプル中で、または複数回用量の容器中で防腐剤と共に、提示され得る。
一部の実施形態では、濃縮γδT細胞集団、及び/またはそれらの混和物は、少なくとも約1ヶ月間、2ヶ月間、3ヶ月間、4ヶ月間、5ヶ月間、6ヶ月間、1年間、2年間、3年間、または少なくとも5年間の長期貯蔵のために、凍結培地中で製剤化され、液体窒素冷凍庫(−195℃)または超低温冷凍庫(−65℃、−80℃、または−120℃)等の極低温貯蔵ユニット内に置かれてもよい。凍結培地は、pHを約6.0〜約6.5、約6.5〜約7.0、約7.0〜約7.5、約7.5〜約8.0、または約6.5〜約7.5に維持するための生理学的pH緩衝剤と共に、ジメチルスルホキシド(DMSO)、及び/または塩化ナトリウム(NaCl)、及び/またはデキストロース、及び/または硫酸デキストラン、及び/またはヒドロキシエチル(hydroyethyl)デンプン(HES)を含有し得る。冷凍保存されたγδT細胞は、解凍され、本明細書に記載されるような抗体、タンパク質、ペプチド、及び/またはサイトカインによる刺激によってさらにプロセスされ得る。冷凍保存されたγδT細胞は、解凍され、本明細書に記載されるようなウイルスベクター(レトロウイルス及びレンチウイルスベクターを含む)または非ウイルス手段(RNA、DNA、及びタンパク質を含む)により遺伝子改変され得る。代替として、非操作型γδT細胞を、本明細書に記載される方法によって増殖させ、遺伝子改変し、冷凍保存することができる。
マウス抗体の形態でのγδTCR活性化因子を、ヒトIgG1FCに融合させたγδTCR鎖の成熟ECDを含む組換えヒト可溶性γ2δ3TCR−FCの免疫化によって生産した。マウスの3つの株(Balb/c、CD−1、及びFVB)にヒト組換えγδTCRを接種して、高親和性のマウスモノクローナル抗体活性化因子を分泌しているハイブリドーマをもたらした。
ELISA結合アッセイに基づいて、δ3可溶性TCRに特異的に結合するいくつかの例となる別個のモノクローナル抗体を配列決定及びさらなる解析のために選択した。図1に表の様式で示されるように、実施例1で生成された選択のモノクローナル抗体の軽鎖可変領域(図)及び重鎖可変領域(図)の配列解析により、新規の相補性決定領域及び新規のVDJ構成の呈示が確認された。図1に記載される相補性決定領域はKabatによる定義に従う。
24ウェルプレート(Corning)に、5μg/mLのヤギ抗マウスIgG抗体300μlを塗布し、一晩置いた。翌日、ウェルをPBSで1回洗浄し、PBS中5%のFBSにより37℃で1時間ブロッキングした。Vδ3抗体を、2%のFBSを含有するPBS中1μg/mLで調製した。300μlの抗体溶液を各ウェルに分注し、室温で2時間インキュベートして、捕捉を行った。
ForteBio Octet機器及び抗ヒトFc AHCバイオセンサ(ForteBio,Pall Corporation,Fremont,CA)を用いて、選択のVδ3抗体を対合における競合パターンに基づいてエピトープビンに分類した。簡潔に述べると、γ2δ3TCR−hFc組換えタンパク質及び全てのVδ3抗体を、20μg/mLのBSAを含有するHBS−PB緩衝液(10mMのHEPES、150mMのNaCl、0.005%のTween−20、pH7.4)中、5μg/mLに希釈した。全ての試料(300μl)を96ウェルプレート中に配置し、製造業者の推奨に従ってOctet 384機器を用いて、競合実験を行った。まず、γ2δ3TCR−hFcを抗ヒトFcバイオセンサ上に5分間捕捉させた。次いで、Vδ3抗体の対を飽和するまで連続してγ2δ3TCR−hFcに結合させて(各々10分間の会合段階)、抗体の対がγ2δ3TCR−hFc上の結合部位を競合するかどうかを決定した。第2の抗体が結合しなかった場合、それら2つの抗体は、同じエピトープビンにあり、同じ、非常に類似した、または主として重複するエピトープを認識すると見なされた。ForteBio HT9.0データ解析ツールを適用して、Vδ3抗体間の競合を決定した。
12ウェルプレート(Corning、CellBIND(登録商標))に、PBS中1μg/mLの精製δ3−08またはδ3−23抗体を600μL/ウェルで直接塗布し、4℃で一晩置いた。翌日、ウェルをPBSで洗浄し、2つのドナー(ドナー3及びドナー4)由来のPBMC(2×106個の総細胞)を活性化のために、10%のFBS、2mMのグルタミン、100IU/mLのrhIL−2(Peprotech)を補充したRPMI−1640培地中1×106細胞/mLで添加した。出発PBMCをフローサイトメトリーによって、Vδ3細胞を含有するVδ1、Vδ2、及び非Vδ1/Vδ2γδT(DN、二重陰性)画分の含量に関して特性評価した。非Vδ1/Vδ2γδT細胞含量は、総細胞の<0.5%であった。2日目及び4日目に、細胞培養物に対して、rhIL−2を補充した新鮮な培地で半交換により栄養補給を行った。
実施例5に記載されるようにδ3−08及びδ3−23MAbを用いて、ドナー3由来のヒトPBMCを活性化させ、CD20 CAR構築物で形質導入した。実施例5に記載されるように、増殖の終わりに、細胞を純度及び形質導入効率に関して特性評価し、αβT細胞を除去した。次いで、αβT細胞が除去された培養物をCD20+ Raji−NucLight Red細胞に対する細胞傷害性アッセイにおいて使用した。CD20+ Raji−NucLight Red細胞は、IncuCyte(登録商標)NucLight Redレンチウイルス粒子で形質導入されており、IncuCyte(登録商標)プラットフォーム上でRaji細胞の蛍光検出が可能である。
Vδ3抗体の結合に必要不可欠であるヒトγδTCRの可変Vδ3領域におけるアミノ酸残基を決定するために、いくつかの点変異、またはそれらの組み合わせをδ3鎖に導入し、Luminexを用いてMAb結合を評定した。簡潔に述べると、Vδ3Vγ9二量体分子のコンピュータモデルを、PDBに寄託されたVδ2Vγ9TCRの結晶構造(受託番号1HXM及び1TVD)を用いて作成した。表1に示されるような可能性のある免疫原性に基づいて、Vδ3鎖の野生型配列に置換を導入した。Vδ3アミノ酸の残基の番号付けは、図12に示される通りである。表1に示される変異型Vδ3鎖を、実施例1に記載されるような293Expi細胞において、ヒト−Fcヘテロ二量体融合タンパク質としてVγ2鎖と共発現させ、プロテインAによる親和性クロマトグラフィーを用いて精製した。変異体及び野生型δ3γ2−hFcタンパク質を、ヤギ−抗ヒトFcポリクローナル抗体とコンジュゲートしたLuminex(登録商標)ビーズ上に捕捉させ、種々のVδ3抗体のEC50結合を決定した。特定の変異体δ3γ2−TCR融合体へのEC50結合の損失または低下を監視して、この変異型アミノ酸の抗原結合への寄与を決定した。理論に拘束されることを望むものではないが、変異に際して結合の減少を示す残基は、Vδ3γδTCRに結合したときのδ3特異的抗体と接触しているとの仮説が立てられる。
Claims (72)
- δ3γδTCRに特有のエピトープに結合する抗体またはその断片。
- 前記抗体またはその断片が、
a)δ3−08、δ3−20、δ3−23、δ3−31、δ3−42、δ3−47、及びδ3−58からなる群から選択される抗体、
b)δ3−08、δ3−23、δ3−31、δ3−42、δ3−47、及びδ3−58からなる群から選択される抗体、
c)δ3−08、δ3−23、δ3−42、及びδ3−58からなる群から選択される抗体、
d)δ3−23、δ3−42、及びδ3−58からなる群から選択される抗体、
e)δ3−31及びδ3−42からなる群から選択される抗体、
f)抗体δ3−08、または
g)抗体δ3−31、
と本質的に同じエピトープに結合する、請求項1に記載の抗体またはその断片。 - 前記抗体またはその断片が、
a)δ3−08、δ3−20、δ3−23、δ3−31、δ3−42、δ3−47、及びδ3−58からなる群から選択される抗体、
b)δ3−08、δ3−23、δ3−31、δ3−42、δ3−47、及びδ3−58からなる群から選択される抗体、
c)δ3−08、δ3−23、δ3−42、及びδ3−58からなる群から選択される抗体、
d)δ3−23、δ3−42、及びδ3−58からなる群から選択される抗体、
e)δ3−31及びδ3−42からなる群から選択される抗体、
f)抗体δ3−08、または
g)抗体δ3−31、
と同じエピトープに結合する、請求項1に記載の抗体またはその断片。 - 前記抗体またはその断片が、
a)δ3−08、δ3−20、δ3−23、δ3−31、δ3−42、δ3−47、及びδ3−58からなる群から選択される抗体、
b)δ3−08、δ3−23、δ3−31、δ3−42、δ3−47、及びδ3−58からなる群から選択される抗体、
c)δ3−08、δ3−23、δ3−42、及びδ3−58からなる群から選択される抗体、
d)δ3−23、δ3−42、及びδ3−58からなる群から選択される抗体、
e)δ3−31及びδ3−42からなる群から選択される抗体、
f)抗体δ3−08、または
g)抗体δ3−31、
の相補性決定領域を含む、請求項1に記載の抗体またはその断片。 - 前記抗体またはその断片が、γδTCRのVδ3に特異的に結合する、請求項1に記載の抗体またはその断片。
- 前記抗体が、Vδ3のγ鎖結合境界面から遠位の領域に結合する、請求項5に記載の抗体。
- 前記抗体が、IMGT命名法による前記γδTCRの前記Vδ3のβストランドD及びEに結合する、請求項5に記載の抗体。
- 前記抗体が、IMGT命名法による前記γδTCRの前記Vδ3のβストランドC’’及びDならびにβストランドEとFとの間のループに結合する、請求項5に記載の抗体。
- 前記抗体が、IMGT命名法による前記γδTCRの前記Vδ3のβストランドA、B、D、及びEに結合する、請求項5に記載の抗体。
- 前記抗体またはその断片が、γδT細胞及びαβT細胞を含む混合細胞集団中で、αβT細胞と比較してδ3γδT細胞を選択的に増殖させる、請求項1〜9のいずれか1項に記載の抗体またはその断片。
- 前記抗体またはその断片が、δ3γδTCRに結合するものである、請求項1〜10のいずれか1項に記載の抗体またはその断片。
- 前記δ3γδTCRが、δ3γδT細胞の表面上で発現される、請求項11に記載の抗体またはその断片。
- 前記抗体またはその断片が、人工抗原提示細胞(aAPC)等の抗原提示細胞(APC)の細胞外表面に結合するものである、請求項1〜12のいずれか1項に記載の抗体またはその断片。
- 前記抗体またはその断片が、前記APCまたはaAPCの膜において係留される、請求項13に記載の抗体またはその断片。
- 前記抗体またはその断片のFc領域が、前記APCまたはaAPCにより発現されるFc受容体に結合するものである、請求項13に記載の抗体またはその断片。
- 前記抗体またはその断片が、
a)δ3−08、δ3−20、δ3−23、δ3−31、δ3−42、δ3−47、及びδ3−58からなる群から選択される抗体、
b)δ3−08、δ3−23、δ3−31、δ3−42、δ3−47、及びδ3−58からなる群から選択される抗体、
c)δ3−08、δ3−23、δ3−42、及びδ3−58からなる群から選択される抗体、
d)δ3−23、δ3−42、及びδ3−58からなる群から選択される抗体、
e)δ3−31及びδ3−42からなる群から選択される抗体、
f)抗体δ3−08、または
g)抗体δ3−31、
に対して結合を競合する、請求項1〜15のいずれか1項に記載の抗体またはその断片。 - 前記抗体またはその断片が、δ3γδT細胞の特異的活性化因子である、請求項1〜16のいずれか1項に記載の抗体またはその断片。
- 請求項1〜17に記載の抗体またはその断片のうちのいずれか1つをコードする核酸であって、前記核酸が、異種プロモーターに作動可能に連結されている、前記核酸。
- 請求項1〜17に記載の抗体もしくはその断片のうちのいずれか1つまたは請求項18に記載の核酸を含む、宿主細胞。
- 前記宿主細胞が人工抗原提示細胞(aAPC)である、請求項19に記載の宿主細胞。
- δ3γδTCRに特有のエピトープに結合する抗体またはその断片の作製方法であって、前記抗体またはその断片を産生させるのに十分な条件下で請求項19に記載の宿主細胞を培養することを含む、前記方法。
- 濃縮γδT細胞集団を生産するためのエクスビボ方法であって、γδT細胞を含む第1の細胞集団を、請求項1〜17に記載の1つまたは複数の抗体またはその断片と接触させることを含む、前記方法。
- 前記第1の細胞集団が、αβT細胞及びγδT細胞を含む単離された混合細胞集団である、請求項22に記載の方法。
- 前記第1の細胞集団が、末梢血単核細胞(PBMC)の試料を含むか、または末梢血単核細胞(PBMC)の試料である、請求項23に記載の方法。
- 前記第1の細胞集団が、末梢血試料、白血球アフェレーシス試料、臍帯血試料、腫瘍試料、または組織試料から選択される、請求項23に記載の方法。
- 前記第1の細胞集団が、1%未満のδ3γδT細胞を含む、請求項23〜25のいずれか1項に記載の方法。
- 前記第1の細胞集団が、培養されていない初代細胞または継代されていない初代細胞を含む、請求項22〜26のいずれか1項に記載の方法。
- 前記方法が、前記単離された混合細胞集団を、前記1つまたは複数の抗体またはその断片と直接接触させることを含む、請求項23〜27のいずれか1項に記載の方法。
- 前記第1の細胞集団が、1つまたは複数の操作型γδT細胞を含む集団である、請求項22に記載の方法。
- 前記第1の細胞集団が、増殖させたγδT細胞の第1の集団である、請求項22または29のいずれか1項に記載の方法。
- 前記方法が、第1のγδT細胞増殖及び第2のγδT細胞増殖を含む、請求項30に記載の方法。
- 前記方法が、少なくとも108個のδ3γδT細胞を含む濃縮γδT細胞集団を生産することを含む、請求項22〜31のいずれか1項に記載の方法。
- 少なくとも108個のδ3γδT細胞を含む前記濃縮γδT細胞集団が、12〜21日以内に生産される、請求項32に記載の方法。
- 前記方法が、前記第1の細胞集団中で前記δ3γδT細胞を、少なくとも1,000倍、好ましくは少なくとも5,000倍、より好ましくは少なくとも10,000倍、または約10,000倍、または少なくとも約10,000倍増殖させることを含む、請求項22〜33のいずれか1項に記載の方法。
- 前記指定の増殖倍率が12〜21日以内に達成される、請求項34に記載の方法。
- 濃縮γδT細胞集団を生産するためのエクスビボ方法であって、
a)γδT細胞を含む第1の細胞集団を、γδT細胞を活性化させ、増殖させる1つまたは複数の第1の活性化剤と接触させて、それによって、増殖させた第1のγδT細胞集団を生産することと、
b)前記増殖させた第1のγδT細胞集団を、γδT細胞を活性化させ、増殖させる1つまたは複数の第2の活性化剤と接触させて、それによって、前記濃縮γδT細胞集団を生産することと、
を含み、前記1つもしくは複数の第1の活性化剤のうちの少なくとも1つまたは前記1つもしくは複数の第2の活性化剤のうちの少なくとも1つが、請求項1〜17のいずれか1項に記載の抗体またはその断片である、前記方法。 - 前記方法が、a)の後かつb)の前に、前記増殖させた第1のγδT細胞集団を単離することを含む、請求項36に記載の方法。
- a)が、抗原提示細胞(APC)及び前記1つまたは複数の第1の活性化剤の存在下で前記第1の細胞集団を培養することを含む、請求項36または37に記載の方法。
- b)が、抗原提示細胞(APC)及び前記1つまたは複数の第2の活性化剤の存在下で前記増殖させた第1のγδT細胞集団を培養することを含む、請求項36または37に記載の方法。
- 前記第1の細胞集団が、αβT細胞及びγδT細胞を含む単離された混合細胞集団である、請求項36〜39のいずれか1項に記載の方法。
- 前記第1の細胞集団が、末梢血試料、白血球アフェレーシス試料、臍帯血試料、腫瘍試料、または組織試料から選択される、請求項40に記載の方法。
- 前記第1の細胞集団が、末梢血単核細胞(PBMC)の試料を含むか、または末梢血単核細胞(PBMC)の試料である、請求項40に記載の方法。
- 前記第1の細胞集団が、培養されていない初代細胞、継代されていない初代細胞を含む、請求項36〜42のいずれか1項に記載の方法。
- 前記第1の細胞集団が、操作型γδT細胞の集団である、請求項36〜39のいずれか1項に記載の方法。
- 前記方法が、前記増殖させた第1のγδT細胞集団を遺伝子改変すること、または前記濃縮γδT細胞集団を遺伝子改変することを含む、請求項36〜44のいずれか1項に記載の方法。
- 前記方法が、少なくとも108個のδ3γδT細胞を含む濃縮γδT細胞集団を生産することを含む、請求項36〜45のいずれか1項に記載の方法。
- 少なくとも108個のδ3γδT細胞を含む前記濃縮γδT細胞集団が、12〜21日以内に生産される、請求項46に記載の方法。
- 前記方法が、前記第1の細胞集団中で前記δ3γδT細胞を、少なくとも1,000倍、好ましくは少なくとも5,000倍、より好ましくは少なくとも10,000倍、または約10,000倍、または少なくとも約10,000倍増殖させることを含む、請求項36〜47のいずれか1項に記載の方法。
- 前記指定の増殖倍率が12〜21日以内に達成される、請求項48に記載の方法。
- 前記1つまたは複数の第1の活性化剤のうちの少なくとも1つが、前記1つまたは複数の第2の活性化剤のうちの少なくとも1つと構造的に同一である、請求項36〜49のいずれか1項に記載の方法。
- 前記1つまたは複数の第1の活性化剤のうちの少なくとも1つが、前記1つまたは複数の第2の活性化剤のうちの少なくとも1つとは構造的に異なる、請求項36〜50のいずれか1項に記載の方法。
- 前記1つもしくは複数の第1の活性化剤のうちの少なくとも1つまたは前記1つもしくは複数の第2の活性化剤のうちの少なくとも1つが固定化されている、請求項36〜51のいずれか1項に記載の方法。
- 前記固定化された活性化剤が、培養容器の表面上に固定化されている、請求項52に記載の方法。
- 前記固定化された活性化剤が、抗原提示細胞(APC)または人工抗原提示細胞(aAPC)の表面上に固定化されている、請求項52に記載の方法。
- 固定化された活性化剤が、δ3γδTCRに特有の前記エピトープに結合する前記抗体またはその断片である、請求項52〜54のいずれか1項に記載の方法。
- 前記方法が、αβT細胞除去の前、またはαβT細胞除去の不在下で、30%超、好ましくは40%超のδ3γδT細胞を達成する、請求項22〜35または36〜55のいずれか1項に記載の方法。
- 増殖させたγδT細胞集団であって、前記増殖させたγδT細胞の30%超、好ましくは40%超、より好ましくは60%超、なおもより好ましくは70%超、さらにより好ましくは80%超がδ3γδT細胞である、前記増殖させたγδT細胞集団。
- 前記増殖させたγδT細胞集団が、ポリクローン性のTCR多様性を含む、請求項57に記載の増殖させたγδT細胞集団。
- 前記δ3T細胞の60超%または70%超が、表現型CD45RA+/CD27+及び/またはCD45RA−/CD27+を発現する、請求項58に記載の増殖させたγδT細胞集団。
- 腫瘍浸潤リンパ球に由来する、請求項57〜59のいずれか1項に記載の増殖させたγδT細胞集団。
- 前記γδT細胞が、内因性または異種腫瘍認識部分を発現する、請求項57〜60のいずれか1項に記載の増殖させたγδT細胞集団。
- 前記集団が治療上有効量のγδT細胞を含む、請求項57〜61のいずれか1項に記載の増殖させたγδT細胞集団。
- 前記γδT細胞集団が、NKp30活性、NKp44活性、及び/またはNKp46活性から独立した抗腫瘍細胞傷害性を含む、請求項57〜62のいずれか1項に記載の増殖させたγδT細胞集団。
- 前記γδT細胞集団が、NKp30活性依存性の抗腫瘍細胞傷害性、NKp44活性依存性の抗腫瘍細胞傷害性、及び/またはNKp46活性依存性の抗腫瘍細胞傷害性を含まない、請求項63に記載の増殖させたγδT細胞集団。
- 前記γδT細胞の40%未満が、検出可能なレベルのNKp30、NKp44、及び/またはNKp46を発現する、請求項57〜63のいずれか1項に記載の増殖させたγδT細胞集団。
- a)請求項22〜35のいずれか1項に記載の方法、または
b)請求項36〜56のいずれか1項に記載の方法、
によって生産される、増殖させたγδT細胞集団。 - がん、炎症性疾患、または自己免疫疾患の処置を必要とする対象における、前記がん、炎症性疾患、または自己免疫疾患の処置方法であって、治療上有効量のδ3γδT細胞を前記対象に投与することを含む、前記方法。
- がん、炎症性疾患、または自己免疫疾患の処置を必要とする対象における、前記がん、炎症性疾患、または自己免疫疾患の処置方法であって、
a)治療上有効量の、請求項57〜66のいずれか1項に記載のδ3γδT細胞を用意することと、
b)前記治療上有効量のδ3γδT細胞を前記対象に投与することと、
を含む、前記方法。 - 前記方法が、前記増殖させたγδT細胞集団を第2の増殖させたγδT細胞集団と混和して、混和集団を形成することと、前記混和集団を前記対象に投与することと、をさらに含む、請求項68に記載の方法。
- 前記第2の増殖させたγδT細胞集団が、>60%のδ1γδT細胞または>60%のδ2γδT細胞を含む、請求項69に記載の方法。
- 前記混和γδT細胞集団が、>60%のδ1γδT細胞または>60%のδ2γδT細胞を含む、請求項69に記載の方法。
- 前記混和γδT細胞集団が、>60%のδ3γδT細胞を含む、請求項69に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762586782P | 2017-11-15 | 2017-11-15 | |
US62/586,782 | 2017-11-15 | ||
PCT/US2018/061384 WO2019099744A1 (en) | 2017-11-15 | 2018-11-15 | METHODS FOR SELECTIVE EXPANSION OF δ3 γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021502816A true JP2021502816A (ja) | 2021-02-04 |
JP2021502816A5 JP2021502816A5 (ja) | 2021-12-23 |
Family
ID=64755702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020526478A Pending JP2021502816A (ja) | 2017-11-15 | 2018-11-15 | δ3γδT細胞集団の選択的増殖方法及びその組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230257462A1 (ja) |
EP (1) | EP3710472A1 (ja) |
JP (1) | JP2021502816A (ja) |
KR (1) | KR20200098518A (ja) |
CN (1) | CN111801349A (ja) |
AU (1) | AU2018370120C1 (ja) |
CA (1) | CA3082818A1 (ja) |
IL (1) | IL274640A (ja) |
MX (1) | MX2020005005A (ja) |
SG (1) | SG11202004506WA (ja) |
WO (1) | WO2019099744A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020117862A1 (en) | 2018-12-03 | 2020-06-11 | Adicet Bio, Inc. | Methods for selective in vivo expansion of gamma delta t-cell populations and compositions thereof |
US20220154144A1 (en) * | 2019-04-26 | 2022-05-19 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial antigen presenting cells comprising ligands for nkg2d for expanding immune cells for immunotherapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016081518A2 (en) * | 2014-11-17 | 2016-05-26 | Adicet Bio, Inc. | Engineered gamma delta t-cells |
WO2016198480A1 (en) * | 2015-06-09 | 2016-12-15 | Lymphact - Lymphocyte Activation Technologies, S.A. | Methods for the production of tcr gamma delta+ t cells |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0633943A4 (en) | 1992-04-03 | 1997-05-02 | Alexander T Young | GENTHERAPY USING TARGETED VIRAL VECTORS. |
JP4968498B2 (ja) | 2002-01-23 | 2012-07-04 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | ジンクフィンガーヌクレアーゼを用いる、標的化された染色体変異誘発 |
US7985739B2 (en) | 2003-06-04 | 2011-07-26 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced sleeping beauty transposon system and methods for using the same |
EP2526112B1 (en) | 2010-01-22 | 2018-10-17 | Dow AgroSciences LLC | Targeted genomic alteration |
JP6082997B2 (ja) | 2011-04-01 | 2017-02-22 | メモリアル スローン−ケタリング キャンサー センター | Hla−a2により提示されるwt1ペプチドへのt細胞受容体様抗体 |
EP2684600A1 (en) | 2012-07-10 | 2014-01-15 | Laboratoires Meiners Sarl | Core-shell capsules and methods for encapsulation of reactive ingredients by diffusional exchange through spherical capsule membranes |
AU2014223243B2 (en) | 2013-03-01 | 2019-10-17 | Regents Of The University Of Minnesota | Talen-based gene correction |
MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
-
2018
- 2018-11-15 SG SG11202004506WA patent/SG11202004506WA/en unknown
- 2018-11-15 EP EP18825814.9A patent/EP3710472A1/en active Pending
- 2018-11-15 CN CN201880085549.1A patent/CN111801349A/zh active Pending
- 2018-11-15 CA CA3082818A patent/CA3082818A1/en active Pending
- 2018-11-15 US US16/764,796 patent/US20230257462A1/en active Pending
- 2018-11-15 KR KR1020207016650A patent/KR20200098518A/ko active Search and Examination
- 2018-11-15 JP JP2020526478A patent/JP2021502816A/ja active Pending
- 2018-11-15 MX MX2020005005A patent/MX2020005005A/es unknown
- 2018-11-15 AU AU2018370120A patent/AU2018370120C1/en active Active
- 2018-11-15 WO PCT/US2018/061384 patent/WO2019099744A1/en active Application Filing
-
2020
- 2020-05-13 IL IL274640A patent/IL274640A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016081518A2 (en) * | 2014-11-17 | 2016-05-26 | Adicet Bio, Inc. | Engineered gamma delta t-cells |
WO2016198480A1 (en) * | 2015-06-09 | 2016-12-15 | Lymphact - Lymphocyte Activation Technologies, S.A. | Methods for the production of tcr gamma delta+ t cells |
Non-Patent Citations (6)
Title |
---|
CLINICAL CANCER RESEARCH, vol. 20, no. 22, JPN6019037021, 2014, pages 5720 - 5732, ISSN: 0005118871 * |
INTERNATIONAL IMMUNOLOGY, vol. VOL:11, NR:4, JPN5021003772, April 1999 (1999-04-01), pages 545 - 552, ISSN: 0005118876 * |
J OF IMMUNOLOGY, 1995, VOL.155, PP.3060-3067, JPN6022043487, ISSN: 0005118874 * |
JOURNAL OF IMMUNOLOGICAL METHODS, vol. VOL:189, NR:1, JPN5021003769, 16 January 1996 (1996-01-16), pages 25 - 36, ISSN: 0005118873 * |
MOL THER., vol. 21(3), JPN6019037022, 2013, pages 638 - 647, ISSN: 0005118872 * |
THE JOURNAL OF CLINICAL INVESTIGATION, vol. NOV;115(11), JPN5021003771, November 2005 (2005-11-01), pages 3140 - 3148, ISSN: 0005118875 * |
Also Published As
Publication number | Publication date |
---|---|
KR20200098518A (ko) | 2020-08-20 |
CA3082818A1 (en) | 2019-05-23 |
EP3710472A1 (en) | 2020-09-23 |
AU2018370120C1 (en) | 2024-05-30 |
WO2019099744A1 (en) | 2019-05-23 |
MX2020005005A (es) | 2020-08-27 |
SG11202004506WA (en) | 2020-06-29 |
AU2018370120A1 (en) | 2020-06-25 |
CN111801349A (zh) | 2020-10-20 |
AU2018370120B2 (en) | 2023-11-09 |
IL274640A (en) | 2020-06-30 |
US20230257462A1 (en) | 2023-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220372439A1 (en) | Methods for selective expansion of gamma delta t-cell populations and compositions thereof | |
JP7317793B2 (ja) | 改変γδT細胞 | |
US20230009275A1 (en) | Methods for expanding gamma delta t-cell populations with multivalent agents and compositions thereof | |
AU2018370120B2 (en) | Methods for selective expansion of d3 yd T-cell populations and compositions thereof | |
US20220218747A1 (en) | Methods for selective in vivo expansion of gamma delta t-cell populations and compositions thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211115 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211115 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221007 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221018 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230418 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231201 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240206 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20240510 |